How fast and how well does ketamine work for severe depression?
Ketamine works much faster than traditional antidepressants. Standard pills like SSRIs often take weeks to lift mood, but ketamine can start working within hours. A study of 120 patients with major depressive disorder found that depression scores dropped significantly just 4 hours after a single ketamine infusion, and the improvement was still there at 24 hours [8]. This speed is a game-changer for people in acute distress.
The effect is also powerful. A meta-analysis (a study that combines results from multiple trials) found that ketamine improved treatment-resistant depression symptoms by nine-fold and reduced suicidal thoughts by three-fold [1]. In a phase 2 trial of 231 patients, 73% experienced rapid remission of their depression after five days of daily ketamine, with their average depression score dropping from severe (31) to mild (13) on a standard scale [2]. These numbers show that for many, ketamine isn't just fast—it's dramatically effective.
Is ketamine only for treatment-resistant depression?
Most of the research focuses on treatment-resistant depression (TRD)—meaning depression that hasn't improved after trying at least two different antidepressants. In that group, the evidence is strongest. For example, a randomized trial comparing ketamine to electroconvulsive therapy (ECT) in severely ill patients found that while ECT was more effective overall, ketamine still produced impressive response and remission rates, making it a viable alternative for people who can't or won't have ECT [5]. Another study showed that ketamine was as effective as ECT for TRD, but with a faster reduction in symptoms [3].
However, ketamine also helps people with severe depression who aren't necessarily 'treatment-resistant.' A study of cancer patients with depression found that ketamine provided rapid relief from depressive symptoms, often within hours to days, along with benefits for anxiety and pain [4]. And in a study of severely depressed inpatients at high risk of suicide, oral ketamine (150 mg over three sessions) dramatically reduced suicidal thoughts—67% of patients went from severe to mild or moderate risk [7]. So while TRD is the main target, ketamine's rapid action makes it useful in other crisis situations.
What are the caveats and risks?
Ketamine isn't a magic bullet, and it comes with important limitations. First, the effects can be short-lived. While a single dose works within hours, the improvement may only last days to a week. That's why treatment often involves a series of infusions (e.g., six over two weeks) and then maintenance doses [5][6]. One study found that after two esketamine (a related drug) sessions, the depression score could predict whether someone would respond long-term, meaning early non-responders might not benefit from continuing [9].
Second, side effects are common but usually temporary. In the short term, people may experience fatigue, dizziness, or a feeling of dissociation (feeling detached from reality) [4]. These effects typically resolve within hours. Long-term safety data are limited, and there is a risk of substance abuse, so ketamine must be carefully supervised, especially in people with a history of addiction [5]. Finally, ketamine is not a standalone cure—it's best used as part of a comprehensive treatment plan that includes psychotherapy and ongoing psychiatric care [6].
About These Sources
This answer is built on 9 peer-reviewed studies — published from 2021 to 2026, 3 from 2024 or later, 5 in Q1 journals, collectively cited 55 times — selected as the most relevant from 11 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
How effective are ketamine or esketamine in treatment-resistant depression?
In a meta-analysis of 11 RCTs, ketamine improved treatment-resistant depression symptoms by nine-fold and reduced suicidality by three-fold; esketamine also improved symptoms (OR=2.61).
Med Check: Esmethadone for Depression; Autism Diagnostic Aid; and More
In a phase 2 trial of 231 patients with treatment-resistant depression, 73% experienced rapid remission after five days of daily ketamine (120 mg), with mean MADRS scores dropping from 31 to 13.
A Comparative Study on the Effectiveness of Electroconvulsive Therapy and Ketamine in Persons Suffering from Treatment-resistant Depressive Disorder
In a randomized trial of 96 patients with treatment-resistant depression, ketamine was as effective as electroconvulsive therapy (ECT) and produced a faster reduction in depressive symptoms.
The Use of Ketamine for Depression in Cancer Patients: A Systematic Review of Efficacy, Safety, and Clinical Applications.
A systematic review of 14 studies in cancer patients found that ketamine provides rapid relief from depressive symptoms within hours to days, with additional benefits for anxiety and pain.
Insights for the Use of Ketamine From Randomized Controlled Trials That Compared Ketamine With Electroconvulsive Therapy in Severe Depression
In five RCTs comparing ketamine to ECT in severely depressed patients, ECT was superior for response and remission rates, but ketamine still showed impressive results and is a viable alternative.
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
The Montreal model describes an integrative approach pairing ketamine infusions with psychotherapy and psychiatric care, aiming to create 'windows of opportunity' for enhanced treatment.
The efficacy of oral ketamine in severely depressed patients at high risk of suicide
In an open-label study of 30 severely depressed inpatients at high suicide risk, oral ketamine (150 mg over three sessions) reduced suicidal ideation scores from severe to mild/moderate in 67% of patients.
An evaluation of the efficacy and side effects of a single dose of ketamine in major depressive disorder
In a retrospective study of 120 patients with major depressive disorder, a single ketamine infusion significantly reduced depression and suicidal ideation scores at 4 and 24 hours post-treatment.
Early effects predict trajectories of response to esketamine in treatment-resistant depression
In a longitudinal study of 105 patients with treatment-resistant depression, the MADRS score after just two esketamine administrations predicted the 90-day trajectory of response with 80% accuracy.
